And then I think as we get into kind of our Q1 earnings, we’ll be able to give a little bit more information as we’ll have a bigger body of evidence. But at this time, we’re not going to get into any more specifics around the timing and the metrics other than to say that we’re tracking as planned and as we previously communicated, and that we’re going to kick off our full commercial launch with a bias towards those RHA customers starting on late March with the training here in Nashville.
Unidentified Analyst: Thank you.
Mark Foley: Sure. Thanks.
Operator: Balaji Prasad with Barclays, your line is open.
Balaji Prasad: Hi, good evening, and thanks for the questions. Couple from me. Firstly with regard to the guidance, can you help me understand if you still have limited visibility to provide guidance, at least on the filler side thought we would see some color around there and maybe your account penetration expectations for DAXI for the year, one. Two, with regard to the sales force side, I mean, we know last year that there was widespread challenges across industries to hire labor. Do you still see those challenges? And if so, it does mean that you’re paying more than the current market prices for these hires. If so, that could help by explain some of the OpEx for this year, which seems to be higher than what we had expected earlier. Thanks.
Mark Foley: Sure. So I’ll take the first one and then maybe I’ll kick the second one over to Dustin to talk about the sales force side and then maybe even Toby on some of the OpEx and what’s underpinning that. But on the guidance for the fillers, hey, listen, we hear you that we’re €“ what two years into our filler launch and that we certainly have a lot more visibility. We’ve been onboarding about 500 accounts a quarter, and so we’ve been very pleased with the traction and the growth that we’ve seen in that market taken into account seasonality. I think the challenge that we have is we know that DAXXIFY is going to introduce yet another new dynamic. When the reps were only selling RHA, it was much easier to estimate and forecast what we thought additional growth might look like.
But now those same reps are going to circle back and they’re going to be the ones that will be introducing DAXXIFY into those accounts. And so in the near-term, we may although it’s €“ we’re not sure, we may see a slowdown in new account adds, for example, however, there’s certainly also some accounts that we’ve not been successful in getting a foothold in. But DAXXIFY might open that door, so we might see some of that as well. And we have roughly 50 new salespeople that we’re going to be adding in Q2 that we expect to be fully up and running by Q3. And so we have a couple of cross currents this year that’s just really hard for us to know exactly what we think that that RHA profile is going to look like. But again, if you up level, we feel very good about our ability to grow RHA this year.
We feel very good about our ability to launch DAXXIFY into the market. We believe we’ve got the right strategy. And as I mentioned earlier, we believe that we can drive our U.S. aesthetics franchise with the products and services that we have to over $1 billion in revenue over time on an annual basis. Dustin, why don’t you comment on the hiring process.
